论文部分内容阅读
自1962年研制成功并临床试用第一个亚硝基脲类抗肿瘤药卡氮芥(BCNU)[1]以来,其衍生物环己亚硝脲(CCNU)[2]和甲环己亚硝脲(Me-CCNU)也分别于1969年及1971年进入临床研究,由于此三者能透过血脑屏
Since its successful development in 1962 and the clinical trial of the first nitrosourea anti-tumor drug BCNU [1], its derivatives of cycloheximide (CCNU) [2] Urea (Me-CCNU) also entered clinical studies in 1969 and 1971 respectively. Since these three can pass through the blood-brain screen